%A Wang Xiang, Zhang Shiqiang, Zhang Youwei %T Clinical research on systemic chemotherapy concurrent whole brain radiotherapy for brain metastases from nonsmall cell lung cancer %0 Journal Article %D 2015 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2015.02.001 %P 81-83 %V 42 %N 2 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_9564.shtml} %8 2015-02-08 %X ObjectiveTo explore the feasibility and safety of systemic chemotherapy concurrent whole brain radiotherapy (WBRT) for nonsmall cell lung cancer (NSCLC) with brain metastases. MethodsEighty cases of NSCLC patients with brain metastases were divided into observation group (40 cases) and the control group (40 cases) according to random number table. Patients were given systemic chemotherapy synchronous WBRT or sequential WBRT. ResultsThe ⅠⅣ degree leukocytopenia incidences of the two groups were 12.5%, 25.0%, 25.0%, 0.0 and 30.0%, 25.0%, 12.5%, 15.0%, and there was statistical significance (χ2=12.12, P<0.05). In the observation group, the total remission rate was 20% (8/40), and it was 22.5% (9/40) in the control group, with no significant difference (χ2=1.79, P>0.05). The median progression free survival of the observation group and of the control group were (3.5±2.3) months and (3.6±1.1) months, respectively, with no significant difference (t=5.23, P>0.05). But the 1years survival rate in the observation group was 37.5% (15/40), significantly higher than that in the control group (17.5%, 7/40), which had statistical significance (χ2=9.11, P<0.05). ConclusionThe safety of systemic chemotherapy synchronous WBRT for NSCLC patients with brain metastases is higher, with good curative effect and strong application feasibility.